Please assess the completion status of the following clinical trial:

Trial Title: Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be able to give informed consent.~* Subjects must meet preliminary criteria for scleroderma.~* Subjects must have diffuse skin involvement.~* Disease must appear to be active as measured by worsening skin score and/or increased ESR.~* Serum SGOT \< 1.5 times upper limit of normal.~* Bilirubin \< 1.5 times upper limit of normal.~* AST/ALT \< 2.5 times upper limit of normal~Exclusion Criteria:~* Any past exposure to Gleevec.~* Women of child bearing potential must be practicing an acceptable form of contraception (OCP, depo-provera, IUD, condoms with spermicidal or sterilization of subject or partner).~* Women who are breastfeeding.~* Men whose partners could conceive must be practicing acceptable contraception (see above).~* Certain abnormal labs including: Neutrophil count \<1.5X109/L, platelets \< 50X109/L.~* Serious comorbidity that may impair the ability to complete the study (such as severe heart disease, severe pulmonary hypertension) and other comorbidities.~* Prednisone at doses of \>10mg/od.~* Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and methotrexate.~* Serious liver disease.~* Creatinine \>200.~* Excluded: Ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin nefazodone, pimozide, propafenone, quinidine, sibutramine and sildenafil where drug interactions could occur.~* Subjects taking endothelin receptor blockers such as bosentan and sitaxsentan.~* Alcohol consumption of \> 3 drinks per week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gleevec (Type: EXPERIMENTAL): Gleevec 200 mg bid for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo coated to appear identical to Gleevec.

Based on this trial design, predict the completion outcome and termination type (if applicable).